GenVec, Inc.

GenVec Signs New Contract to Support HIV and Influenza Vaccine Development [Press Release]
PRNewswire | 18 days 22 hours 5 minutes ago
...5 /PRNewswire-FirstCall/ -- GenVec, Inc. announced today that SAIC-Frederick...currently in clinical testing. GenVec, Inc. is a biopharmaceutical company...Investor Contact: Media Contact: GenVec, Inc. Tiberend Strategic Advisors...

GenVec Reports Third Quarter 2009 Financial Results [Press Release]
PRNewswire | 18 days 13 hours 41 minutes ago
GAITHERSBURG, Md., Nov. 5 /PRNewswire-FirstCall/ -- GenVec, Inc.

GenVec to Present at Merriman Curhan Ford's Investor Summit 2009 [Press Release]
PRNewswire | 20 days 21 hours 11 minutes ago
...PRNewswire-FirstCall/ -- Today GenVec, Inc. announced that Paul H. Fischer...will be accessible for 30 days. GenVec, Inc. is a biopharmaceutical company...Investor Contact: Media Contact: GenVec, Inc. Tiberend Strategic Advisors...

FDA Grants Orphan Drug Designation for TNFerade(TM) [Press Release]
PRNewswire | 19 days 22 hours 14 minutes ago

GenVec Announces Third Quarter 2009 Results Conference Call [Press Release]
PRNewswire | 27 days 11 minutes ago
...28 /PRNewswire-FirstCall/ -- GenVec, Inc. announced that it will release...click on "Webcasts and Data." GenVec, Inc. is a biopharmaceutical company...Investor Contact: Media Contact: GenVec, Inc. Tiberend Strategic Advisors...

GenVec Receives NASDAQ Notice of Minimum Bid Price Non-Compliance [Press Release]
PRNewswire | 69 days 4 hours 25 minutes ago
...FirstCall/ -- On September 15, 2009, GenVec, Inc. received a notice from The NASDAQ...minimum bid price requirement. GenVec, Inc. is a biopharmaceutical company...INVESTOR CONTACT: MEDIA CONTACT: GenVec, Inc. Tiberend Strategic Advisors...

GenVec Receives National Cancer Institute Grant to Expand Cancer Program [Press Release]
PRNewswire | 55 days 4 hours 56 minutes ago
...30 /PRNewswire-FirstCall/ -- GenVec, Inc. announced today that it has received...severely unmet medical need." GenVec, Inc. is a biopharmaceutical company...Investor Contact: Media Contact: GenVec, Inc. Tiberend Strategic Advisors...

GenVec Receives Fourth-Year Funding From NIAID For HIV Vaccine Contract [Press Release]
PRNewswire | 61 days 5 hours 25 minutes ago
...24 /PRNewswire-FirstCall/ -- GenVec, Inc. announced today that the National...adenovirus serotype technology. GenVec, Inc. is a biopharmaceutical company...Investor Contact: Media Contact: GenVec, Inc. Tiberend Strategic Advisors...

GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants [Press Release]
PRNewswire | 89 days 4 hours 55 minutes ago
...27 /PRNewswire-FirstCall/ -- GenVec, Inc. announced today that it has entered...solicitation, or sale is unlawful. GenVec, Inc. is a biopharmaceutical company...Desk photodesk@prnewswire.com GenVec, Inc. CONTACT: Danielle M. DiPirro...

GenVec Reports Second Quarter 2009 Financial Results [Press Release]
PRNewswire | 109 days 20 hours 25 minutes ago
GAITHERSBURG, Md., Aug. 6 /PRNewswire-FirstCall/ -- GenVec, Inc.

GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development [Press Release]
PRNewswire | 91 days 5 hours 26 minutes ago
...25 /PRNewswire-FirstCall/ -- GenVec, Inc. announced today that it has received...Director of Vector Sciences. GenVec, Inc. is a biopharmaceutical company...Desk photodesk@prnewswire.com GenVec, Inc. CONTACT: Danielle M. DiPirro...

Research and Markets: Ophthalmic Pharmaceutical Drugs - A Global Market Perspective [Press Release]
Business Wire | 6 days 5 hours 59 minutes ago
Research and Markets (http://www.researchandmarkets.com/research/4e2e61/ophthalmic_pharmac) has announced the addition of the "Ophthalmic Pharmaceutical Drugs - A Global Market Perspective" report to their offering.

VIVALIS ACCELERATES MARKETING OF EB66 CELL LINE IN NORTH AMERICA [Press Release]
MarketWire | 41 days 19 hours 27 minutes ago
NANTES, FRANCE -- (Marketwire) -- 10/13/09 -- VIVALIS (NYSE Euronext Paris: VLS), a biopharmaceutical company that provides the pharmaceutical industry with innovative cell-based solutions for the manufacture of vaccines and proteins and develops drugs to prevent and treat viral diseases, announces today that they executed an agreement with Louis J. Cantolupo to accelerate the marketing of the EB66® cell line in North America, principally in monoclonal antibodies and the therapeutic proteins.